AZN
NEUTRALAstraZeneca Appoints New Head of Investor Relations
The pharmaceutical company has appointed a new head of its investor relations team.
AstraZeneca
14,026.00GBX
-2.23%
Market Cap
217.44B
Volume
2.7M
127% of avg
P/E Ratio
1814.18
EPS (TTM)
7.73
Beta
0.19
Day Range
13,982.00p - 14,410.00p
52 Week Range
9,573.50p14,026.00p15,474.36p
14,026.00p
Upcoming Events
10 February 2026
Announcement of FY and Q4 2025 results
High Impact Event
Late 2026
Opening of AstraZeneca's second major R&D centre in Cambridge, Massachusetts
High Impact Event
AZN
NEUTRALAstraZeneca Announces Director Share Sale
The pharmaceutical company has announced a non-executive director's sale of ordinary shares.
AZN
NEUTRALAstraZeneca's Enhertu granted Breakthrough Therapy Designation in the US for post-neoadjuvant early breast cancer
The biopharmaceutical company AstraZeneca announced that its cancer drug Enhertu has been granted Breakthrough Therapy Designation in the US for treating certain patients with HER2-positive early breast cancer.
AZN
NEUTRALAstraZeneca's LATIFY Phase III trial of ceralasertib plus Imfinzi fails to meet primary endpoint in lung cancer
The biopharmaceutical company's trial of a combination therapy for lung cancer patients did not achieve its primary goal.
AZN
NEUTRALAstraZeneca Director Gifts Shares to Spouse
The pharmaceutical company announces a non-executive director has gifted shares to his spouse.
AZN
NEUTRALAstraZeneca's Saphnelo approved for subcutaneous self-administration in EU for lupus
The healthcare company has received European approval for a subcutaneous version of its lupus treatment Saphnelo, providing patients with a new self-administration option.
AZN
NEUTRALAstraZeneca's Enhertu approved in US for first-line HER2-positive metastatic breast cancer
The biopharmaceutical company announced that its HER2-directed antibody drug conjugate Enhertu has been approved in the US for the first-line treatment of HER2-positive metastatic breast cancer.
AZN
NEUTRALAstraZeneca Announces Change in Major Shareholding
The pharmaceutical company has reported a change in major shareholding, with The Capital Group Companies, Inc. reducing its stake in the business.
AZN
NEUTRALAstraZeneca's Imfinzi approved in US for early gastric cancer
The healthcare company announced that its cancer drug Imfinzi has been approved in the US for the treatment of early-stage gastric and gastroesophageal cancers.
AZN
NEUTRALAstraZeneca to invest $2 billion in Maryland manufacturing expansion
The pharmaceutical company plans a major $2 billion investment to expand its manufacturing capabilities in Maryland, supporting 2,600 jobs.